These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24596453)

  • 1. Therapeutic vaccines and cancer: focus on DPX-0907.
    Karkada M; Berinstein NL; Mansour M
    Biologics; 2014; 8():27-38. PubMed ID: 24596453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.
    Berinstein NL; Karkada M; Morse MA; Nemunaitis JJ; Chatta G; Kaufman H; Odunsi K; Nigam R; Sammatur L; MacDonald LD; Weir GM; Stanford MM; Mansour M
    J Transl Med; 2012 Aug; 10():156. PubMed ID: 22862954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.
    MacDonald LD; MacKay A; Kaliaperumal V; Weir G; Penwell A; Rajagopalan R; Langley JM; Halperin S; Mansour M; Stanford MM
    Hum Vaccin Immunother; 2018 Jan; 14(1):59-66. PubMed ID: 28933663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration.
    Karkada M; Quinton T; Blackman R; Mansour M
    ISRN Oncol; 2013; 2013():753427. PubMed ID: 23533812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control.
    Brewer KD; Weir GM; Dude I; Davis C; Parsons C; Penwell A; Rajagopalan R; Sammatur L; Bowen CV; Stanford MM
    J Biomed Sci; 2018 Jan; 25(1):7. PubMed ID: 29374458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
    Berinstein NL; Karkada M; Oza AM; Odunsi K; Villella JA; Nemunaitis JJ; Morse MA; Pejovic T; Bentley J; Buyse M; Nigam R; Weir GM; MacDonald LD; Quinton T; Rajagopalan R; Sharp K; Penwell A; Sammatur L; Burzykowski T; Stanford MM; Mansour M
    Oncoimmunology; 2015 Aug; 4(8):e1026529. PubMed ID: 26405584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.
    DeBay DR; Brewer KD; LeBlanc SA; Weir GM; Stanford MM; Mansour M; Bowen CV
    Mol Ther Methods Clin Dev; 2015; 2():15048. PubMed ID: 26730395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
    Smith HA; McNeel DG
    J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide vaccines in breast cancer: The immunological basis for clinical response.
    Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
    Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
    J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of an HPLC/UV assay for separation and quantification of peptide antigens from a liposomal vaccine delivery platform.
    Penwell A; Sharp K; Mansour M; Sammatur L
    J Pharm Biomed Anal; 2012 Jul; 66():176-82. PubMed ID: 22516680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.
    Smith HA; Rekoske BT; McNeel DG
    Vaccine; 2014 Mar; 32(15):1707-15. PubMed ID: 24492013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
    Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
    Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.